| Registry | NCT07624929, acronym EVLA+VR |
|---|---|
| Status | Enrolling by invitation |
| Phase | Not applicable |
| Study type | Interventional; na, single group, masking: none, supportive care |
| Enrollment | 100 (Estimated) |
| Sponsor | Bydgoszcz University of Science and Technology (Other) |
| Conditions | Chronic Venous Insufficiency, CVI |
| Interventions | VR (VR-Control) (Device) |
| Dates | start 2026-06-10 (estimated), primary completion 2028-05-10 (estimated), completion 2028-09-10 (estimated), first posted 2026-06-03, last updated 2026-06-09 |
| Locations | 1 site in Poland |
Related Papers Related Patents Related Grants Related Experts
All trials for Chronic Venous Insufficiency, CVI All trials of VR (VR-Control)
This is a prospective, single-arm, pre-post interventional study designed to evaluate the feasibility, safety, and impact of immersive virtual reality (VR) as an adjunct to tumescent local anesthesia during endovenous laser ablation (EVLA) for varicose veins / chronic venous insufficiency. All eligible and consenting participants will receive the same intervention (immersive VR during the entire EVLA procedure). There is no randomization, no control group, and no allocation to different arms. Each participant serves as their own control through before-and-after comparisons
This prospective single-arm interventional study with a pre-post design aims to assess the effect of immersive virtual reality (VR) on procedural anxiety, pain perception, cybersickness, sense of presence, usability, and overall patient satisfaction during ambulatory endovenous laser ablation (EVLA) performed under tumescent local anesthesia (TLA).
All consenting adult patients scheduled for unilateral or bilateral EVLA of the great saphenous vein (GSV), small saphenous vein (SSV), or accessory veins due to symptomatic chronic venous insufficiency (CEAP C2-C6) will be enrolled. There is no control group: every participant who provides informed consent will receive immersive VR (using a head-mounted display with relaxing/immersive nature-based content) starting 5-10 minutes before tumescent infiltration and continuing throughout the procedure (\~30-60 minutes).
Key outcome measures will be collected at multiple time points:
Baseline (pre-procedure): hemodynamic parameters, saturation, technology experience, baseline anxiety and pain (VAS / NRS), every 5 minutes during the procedure and right after the surgical procedure, cybersickness (SSQ), satisfaction and any adverse events.
Technology-Focused Objective
• To evaluate usability and tolerability of VR technology in a real clinical setting, including:
* comfort of use during a medical procedure
* interaction with the device during limited mobility
* feasibility of VR integration into procedural workflow
Follow-up (4-6 weeks): delayed pain, satisfaction, technology experience, and adverse events.
The primary endpoint is the change in procedural anxiety (VAS) from pre- to post-procedure. Secondary endpoints include change in pain (NRS) and hemodynamic profile, cybersickness severity, presence scores, usability, patient satisfaction, and safety profile of VR in this setting.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Adult patients, scheduled to EVLA procedure under local anesthesia. | Experimental | Device: VR (VR-Control) | exclusion of epilepsy, severe motion sickness, previous severe cybersickness |
Sex: All, ages: 18 Years to any
Inclusion Criteria: * adults people scheduled to EVLA under local anesthesia and signed for VR interventiion. Exclusion Criteria: * exclusion of epilepsy, severe motion sickness, previous severe cybersickness
| Facility | City | Country | Status |
|---|---|---|---|
| Bydgoszcz Univ of Science and Technology | Bydgoszcz | Poland |